Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 6:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 5,126 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acquired Immunodeficiency Syndrome (AIDS) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Influence of Reproductive Cycle and Menopause on HIV-1 Infection and TFV Gel Activity

NCT01810315
View directory record Official record
Conditions
HIV Prevention
Interventions
TFV 1% gel, Estradiol vaginal cream
Drug
Lead sponsor
CONRAD
Other
Eligibility
21 Years to 89 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 10, 2015 · Synced Oct 6, 2026, 6:29 PM EDT
Completed Not applicable Interventional Results available

Computer-based Intervention for Alcohol-using HIV/HCV+ Women

NCT03362476
View directory record Official record
Conditions
Human Immunodeficiency Virus, Hepatitis C, Alcohol Abuse
Interventions
Computer-based alcohol reduction intervention, Brief clinician-delivered MET, Standard of care
Behavioral
Lead sponsor
New York University
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 6, 2026, 6:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Acute Neural and Immune Effects of Alcohol in People Living With HIV Infection

NCT04050735
View directory record Official record
Conditions
HIV-1-infection, Alcohol Drinking
Interventions
Alcohol, ethyl, moderate dose, Placebo
Other
Lead sponsor
Brown University
Other
Eligibility
21 Years to 60 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 6, 2026, 6:29 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections

NCT00001035
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Interferon alfa-2b, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
3
States / cities
Los Angeles, California • Indianapolis, Indiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Oct 6, 2026, 6:29 PM EDT
Withdrawn No phase listed Observational

Predictors of Time to Viremia With an Analytic Treatment Interruption

NCT03033017
View directory record Official record
Conditions
HIV
Interventions
Blood Testing
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
San Francisco, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 6, 2026, 6:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The HIV Testing Using Enhanced Screening Techniques in Emergency Departments Trial

NCT01781949
View directory record Official record
Conditions
Rapid HIV Screening
Interventions
A: Nontargeted rapid HIV screening, B: Enhanced targeted rapid HIV screening, C: Traditional targeted rapid HIV screening
Other
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
16 Years and older
Enrollment
76,235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
4
States / cities
Oakland, California • Denver, Colorado • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 6, 2026, 6:29 PM EDT
Completed Phase 2 Interventional Results available

Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients

NCT00085917
View directory record Official record
Conditions
Hepatitis C, HIV Infections
Interventions
Double dose pegylated interferon with weight based Ribavirin, standard dose pegylated interferon alfa -2a and ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 6, 2026, 6:29 PM EDT
Completed Phase 2 Interventional Results available

Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial

NCT01177059
View directory record Official record
Conditions
HIV-1
Interventions
OZ1 transduced cells
Genetic
Lead sponsor
Janssen-Cilag Pty Ltd
Industry
Eligibility
Not listed
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2017
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 6, 2026, 6:29 PM EDT
Completed Phase 2 Interventional Results available

High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With HIV

NCT02841774
View directory record Official record
Conditions
HIV Infection, Coronary Heart Disease
Interventions
Pravastatin, Rosuvastatin
Drug
Lead sponsor
Matthew Feinstein
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 6, 2026, 6:29 PM EDT
Completed No phase listed Observational

IMPAACT 2015 - Evaluation of the HIV-1 Reservoir in the Central Nervous System of Perinatally-Infected Youth and Young Adults With Cognitive Impairment

NCT03416790
View directory record Official record
Conditions
HIV-1-infection
Interventions
Not listed
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
13 Years to 24 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 6, 2026, 6:29 PM EDT
Completed Phase 3 Interventional

Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy

NCT00064623
View directory record Official record
Conditions
HIV Infections, Peripheral Nervous System Diseases, Pain
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
35
States / cities
Phoenix, Arizona • Berkeley, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2008 · Synced Oct 6, 2026, 6:29 PM EDT
Completed Not applicable Interventional

Directly Observed Therapy for HIV Infected Adolescents

NCT00259389
View directory record Official record
Conditions
HIV Infections
Interventions
Directly observed therapy (DOT)
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 25 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Oct 6, 2026, 6:29 PM EDT
Completed Phase 3 Interventional

Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease

NCT00002145
View directory record Official record
Conditions
HIV Infections, Gastrointestinal Diseases
Interventions
Foscarnet sodium
Drug
Lead sponsor
Astra USA
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
15
States / cities
Berkeley, California • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 6, 2026, 6:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761

NCT01031472
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK2248761 formulation 1, GSK2248761 reference formulation, GSK2248761 formulation 3, GSK2248761 formulation 2 or 4
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 6, 2026, 6:29 PM EDT
Completed Phase 2 Interventional Results available

Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults

NCT01685372
View directory record Official record
Conditions
Solid Organ Transplant Recipient (Liver, Kidney, Heart), Rheumatologic Disorder, Human Immunodeficiency Virus (HIV), Bone Marrow Transplant (BMT), Dialysis
Interventions
Fluzone High Dose, Fluzone
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
5 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 6, 2026, 6:29 PM EDT
Completed No phase listed Observational

Blood Markers of Inflammation, Blood Clotting and Blood Vessel Function in HIV-infected Adults

NCT00776412
View directory record Official record
Conditions
Inflammation, Pathologic Processes
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 100 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 6, 2026, 6:29 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

NCT02707601
View directory record Official record
Conditions
HIV-1 Infection, HCV Infection
Interventions
E/C/F/TAF, F/R/TAF, LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 6, 2026, 6:29 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Multidisciplinary Low-Barrier and Mobile HIV Care to Improve Retention and Viral Suppression: Stakeholder-Engaged Design and Evaluation

NCT05887557
View directory record Official record
Conditions
HIV
Interventions
Active Referral, Drop-In Multidisciplinary HIV Care, Mobile HIV Care, Staged Care, Identify and prepare champions at referral sites, Audit and feedback at referral sites, Build a coalition among referral and clinical sites, Assess for readiness and identify barriers, Promote adaptability, Develop a formal implementation blueprint, Develop educational materials; conduct ongoing training, Create a learning collaborative
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
15 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
5
States / cities
Oakland, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 6, 2026, 6:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Steering Together in a New Direction: Reducing the Risk of HIV/STD Among African American Men

NCT02572401
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), Sexually Transmitted Disease (STD)
Interventions
STAND HIV Risk Reduction Intervention, Text Messaging Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
391 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 6, 2026, 6:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Healthy Volunteer And Patient Study To Assess The Safety, Tolerability And Pharmacokinetics Of GSK1265744

NCT00659191
View directory record Official record
Conditions
HIV Infection
Interventions
GSK1265744
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Orlando, Florida • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2010 · Synced Oct 6, 2026, 6:29 PM EDT
Completed No phase listed Observational

Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes

NCT02650024
View directory record Official record
Conditions
Hepatitis C, Human Immunodeficiency Virus
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 6, 2026, 6:29 PM EDT
Enrolling by invitation Not applicable Interventional

A Spatial Analysis of Hotspots and Targeted Injection Settings Pilot Intervention for HIV Prevention Among People Who Inject Drugs

NCT05769023
View directory record Official record
Conditions
COVID-19
Interventions
Intervention test
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 6, 2026, 6:29 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Antiretroviral Agents in HIV-1 Infected Pregnant Women

NCT00006320
View directory record Official record
Conditions
HIV Infection
Interventions
determine blood levels of anti-HIV drugs
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 6, 2026, 6:29 PM EDT
Completed Phase 2 Interventional

Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315

NCT00000891
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Saquinavir, Delavirdine mesylate, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
3
States / cities
Denver, Colorado • Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 6, 2026, 6:29 PM EDT